Eloralintide
Research Guide

Research Overview

Eloralintide (research code LY-3841136, also cataloged as AMY-1176) is a synthetic peptide studied as a selective agonist of the amylin receptor family. It is characterized in the literature as an engineered amylin analog, with in-vitro and preclinical work describing preferential activation of the amylin 1 receptor (AMY1R) subtype relative to the calcitonin receptor and the amylin 3 receptor. Its INN, eloralintide (INN List 131), and its USAN designation carry the -lintide amylin-mimic stem assigned in 2024.

The compound is registered in ChEMBL as CHEMBL6068462 (molecule type: protein; single stereoisomer; reported at clinical phase 2 in that database). No PubChem CID was returned for eloralintide, LY3841136, or LY-3841136 in this reference build, and ChEMBL stores no chemical structure for the molecule. As a result, the chemical-identity values below (CAS number, molecular formula, molecular weight) originate from vendor catalogs rather than a primary chemistry database and are flagged for confirmation against the batch certificate of analysis (COA).

This page summarizes reported research context only. Nothing here describes or implies a human or veterinary use, therapeutic benefit, dose, or medical application. All figures are drawn from in-vitro assays and preclinical or early-phase research literature and are presented for laboratory reference.

Mechanism Summary

Mechanisms reported in the in-vitro and preclinical research literature include:

• Amylin receptors are heterodimeric complexes formed by the calcitonin receptor (CTR) paired with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), producing the AMY1R, AMY2R, and AMY3R subtypes. Eloralintide is described in the discovery literature as an amylin analog engineered for AMY1R selectivity.
• In cell-based functional assays reported by Briere and colleagues (Mol Metab 2025), eloralintide preferentially activated human AMY1R (reported EC50 23.9 pM) with approximately 12-fold selectivity over human CTR (reported EC50 291.0 pM) and approximately 11-fold over human AMY3R (reported EC50 253.8 pM). In rat assays it activated AMY1R (reported EC50 5.4 pM) more potently than CTR (reported EC50 243.2 pM), described as roughly 45-fold selectivity, and also potently activated rat AMY3R (reported EC50 13.8 pM).
• Structurally, the discovery paper describes a 37-residue main chain in which the native amylin disulfide is replaced by a methylene thioacetal bridge, Lys26 is acylated with a side chain incorporating a saturated linear 20-carbon diacid, the C-terminus is amidated, and three non-coded amino acid residues sit at positions 11, 15, and 22. These modifications are reported as design features intended to confer receptor selectivity and an extended circulating profile relative to native amylin.
• In preclinical rat models the reported effect was a dose-dependent reduction in food intake and body weight, described as primarily fat-mass loss, with investigators framing the mechanism as amylin-receptor-mediated modulation of satiety and fullness signaling. Reported early-phase human pharmacokinetics included a terminal half-life of approximately 310 to 366 hours (about 12.9 to 15.3 days). All values are in-vitro or preclinical and early-clinical research findings; no human efficacy or dosing claim is made here.
• AMY2R potency was not reported in the retrieved discovery paper, so the full subtype-selectivity profile at AMY2R is unconfirmed.

Reference Data

Identity values are compiled from public chemistry databases and vendor documentation. Confirm the exact salt form, molecular weight, and purity for a given batch against its Certificate of Analysis (COA).

Research Applications

In laboratory research, Eloralintide is studied in contexts such as:

• Studied in vitro for amylin receptor subtype selectivity and full-agonist pharmacology across human and rat AMY1R, AMY3R, and CTR (receptor-selectivity characterization)
• Investigated preclinically in diet-induced obese rats for dose-dependent reductions in food intake and body weight, reported with a fat-mass-selective composition of weight change
• Studied preclinically as a comparator to the non-selective amylin agonist cagrilintide, including a reported reduction in conditioned taste avoidance in lean rats (tolerability and aversion-signal research)
• Investigated as a selective amylin receptor agonist within research programs on chronic weight regulation in obesity and overweight models (early-phase through later-phase clinical research contexts, e.g. NCT05295940, NCT06230523)
• Investigated in early-phase combination research alongside agents such as the GLP-1/GIP agonist tirzepatide and the peptide macupatide, alone or in combination (e.g. NCT06297616, NCT06345066, NCT06603571, NCT07215559)
• Included as a comparator agent in network meta-analyses of amylin-based agents for weight and gastrointestinal-tolerability research outcomes
• Studied in special-population pharmacokinetics research contexts, including renal-impairment (NCT07426380) and hepatic-impairment (NCT07401862) protocols, and in metabolism and insulin-sensitivity research (NCT07665879)
• Investigated in research contexts beyond weight alone, including obesity-associated knee osteoarthritis pain (NCT07353931) and obesity-associated obstructive sleep apnea (NCT07369011)

Storage Information

• Store the lyophilized peptide per the batch COA and product documentation. As a general reference for lyophilized peptides, cold, dry, dark storage with protection from light and repeated temperature cycling is typical; confirm the exact storage temperature and shelf life against the COA for this material.
• Reconstitution solvent, working concentration, in-solution stability, and freeze/thaw handling for this catalog item were not established from primary literature in this build. Defer these to the COA and product documentation.
• See the Lyophilized Storage Guide for general handling of lyophilized research peptides, and use the Reconstitution Calculator to plan working stock concentrations once the intended assay volumes are known.
• Aliquot reconstituted material to minimize freeze/thaw cycles, and confirm identity and purity against the COA before use.